|
|
Article: Metformin for Prevention of Weight Gain and Insulin Resistance With Olanzapine: A Double-Blind Placebo-Controlled Trial
- Article from:
- Canadian Journal of Psychiatry
- Article date:
- March 1, 2006
- Author:
-
;
;
;
;
;
;
|
Copyright informationCopyright Canadian Psychiatric Association Mar 2006. Provided by ProQuest LLC. (Hide copyright information)
|
Objective: To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine.
Method: Forty patients taking olanzapine (10 mg daily) were randomly allocated to a metformin (n = 20; 850 to 1700 mg daily) or placebo (n = 20) group in a 14-week double-blind study. Waist circumference (WC), BWG, body mass index (BMI) fasting glucose, insulin, and lipids were evaluated at baseline and at Weeks 7 and 14 of treatment.
Results: At Week 14, BWG (kg) was similar in the metformin group (5.5 kg) and the placebo group (6.3 kg), P = 0.4. There were no differences between the changes in BMI, WC, glucose, insulin, insulin ...